Livalo

• 

  LIVALO package insert

  Scan the QR code linked to package insert.

  

• Livalo® pitavastatin is a fully synthetic and highly potent statin available across Asia, Europe, Latin America and North America.
  It is indicated for Patients with primary hyperlipidemia including familial hypercholesterolaemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) and children aged 10 years and older with familial hypercholesterolemia when response to diet and other non-pharmacological measures are inadequate.

  Since there is no experience of use in homozygous cases of familial hypercholesterolemia, administration of LIVALO should be considered as a treatment supplementary to non-drug therapy such as LDL-apheresis and only when treatment with LIVALO is judged indispensable.
  Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure and has confirmed its place in the statin armamentarium, particularly for patients who require high-density lipoprotein cholesterol (HDL-C) raising or where poly-pharmacy exists, with a risk of drug-to-drug interactions.
  A study conducted in Japan demonstrated that pitavastatin did not increase the risk of developing diabetes in a large group of patients with impaired glucose tolerance.